April 28, 2020 AACR 2020 – Gracell validates a novel Car-T target The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.
April 17, 2019 Kiadis moves to reduce reliance on its in-house lead Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
